CMV-specific T cell therapy - Juno Therapeutics

Drug Profile

CMV-specific T cell therapy - Juno Therapeutics

Alternative Names: CMV-Streptacells - Juno Therapeutics; STAGE CMV-Streptacells

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stage Cell Therapeutics
  • Developer Juno Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cytomegalovirus infections

Most Recent Events

  • 11 May 2015 Stage Cell Therapeutics has been acquired by Juno Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top